

Editorial

Bronchoscopy in Severe Asthmatics: Is it a Safe Procedure?



Asthma is a heterogeneous disease that is characterized by airway inflammation resulting in airway hyperresponsiveness.¹ Currently, a percentage of asthma patients fail to achieve an adequate control of the disease with standard asthma medications and require oral corticosteroids to control their symptoms. In the last years, we are moving toward a precise phenotyping using imaging and different biomarkers aiming at personalization of asthma therapy with some provocative results.² In this context, the use of tissue biomarkers such as induced sputum or bronchoscopy samples have been proposed as useful tools in the work-up of severe asthma. Notably, the lack of access to induced sputum in most centers and the perception that bronchoscopy could be unsafe in patients with severe asthma are bottlenecks in the progression toward a more precise phenotyping. In our experience using both techniques, we would like to justify the usefulness and safety of bronchoscopy in the work-up of severe asthma patients.

Bronchoscopy is a minimally invasive technique that was firstly used in 1907 to study an asthma case with favorable results.³ After the appearance of flexible bronchoscopy, it was extensively used in the 1980s and 1990s as a research tool to study airway physiology, airway inflammation and pathological changes in adults with asthma.⁴ Few studies reported the safety of bronchoscopy in asthma patients⁵ with a debate in its use in those with FEV₁ less than 60%. Elston et al.⁶ and Moore et al.⁷ performed bronchoscopy to severe asthma cases with FEV₁ 55% predicted and they found that the procedure including bronchoalveolar lavage (BAL) and endobronchial biopsy were well tolerated and safe among this subpopulation of asthma. Earlier, Van Vyve et al.⁵ performed bronchoscopy without premedication with bronchodilators for asthma population where some of them had a FEV₁ of 37% and the researchers found no significant fall in spirometric parameters after the procedure; the associated decrease in arterial oxygen saturation was not correlated with disease severity. Thus, Van Vyve et al.⁵ concluded that bronchoscopy is well tolerated and safe in patients with asthma. Similarly, Humbert et al.⁸ found that bronchoscopy and bronchial biopsy were well tolerated in asthmatic patients with similar fall in PEFR in both asthmatics and non-asthmatics; however, they reported bronchospasm in relation to BAL, but no delayed effect on asthma control was detected after 2 weeks of follow up.

Severe uncontrolled asthma patients have also been explored with bronchoscopic sampling. Good et al.⁹ identified 5 different subgroups of asthma: subacute bacterial infection, tissue eosinophilia, gastroesophageal reflux disease, combination and

nonspecific phenotypes. More recently, Cosio et al.¹⁰ studied 100 consecutive asthma patients with severe uncontrolled disease whom underwent bronchoscopy with bronchial biopsy as a part of their evaluation. They identified 3 different clinical clusters: upper airway, infection and nonspecific. 50% of the later cluster had submucosal eosinophilia while submucosal eosinophilia was less frequently found in the infection phenotype. Interestingly, both Good et al.⁹ and Cosio et al.¹⁰ found 43% and 27% of their asthma population respectively had bacterial infection in their samples. Further, both researchers' groups reported that bronchoscopy is a safe procedure in the asthma population. The analysis of the implications of these microbiological findings on asthma control would deserve a detailed analysis, but it serves to comment on the safety of the procedure in both studies with severe asthma.

Bronchial thermoplasty (BT) studies for asthma also provide data on the safety of the procedure. BT is an endoscopic treatment for severe and uncontrolled asthma patients despite adequate medical treatment. Gordon et al.¹¹ developed a histopathological score of structural not inflammatory bronchial changes in bronchial biopsy for the evaluation of persistent severe asthma patient prior to BT. They found that BT significantly reduced the airway smooth muscle prominence. Similarly, Pretolani et al.¹² found that BT effectively reduce the airway smooth muscle in refractory asthma as assessed by bronchial biopsy. Ichikawa et al.¹³ found also that BT reduce the airway smooth muscle prominence but not reducing airway inflammation or affecting the endobronchial vasculature. None of the authors reported complications in relation to bronchoscopy and bronchial biopsy. Muñoz-Fernández et al. also described the safety of a modified protocol of BT.¹⁴

Currently, possible implications for the selection of treatments can be glimpsed. In the era of biological therapy, blood eosinophilia, IgE and FeNO are the biomarkers commonly used as a biomarker for T2 inflammation and direct the use of biological therapy. However, Cosio et al.¹⁵ found that 5.4% patients with blood eosinophilia had no tissue eosinophilia in submitted bronchial biopsies and on the contrary others (37.5%) had tissue eosinophilia but not in blood. Moreover, Cosio et al.¹⁵ validated a standardized pathological score (modified from Gordon et al.¹¹) in the systematic assessment of the bronchial biopsy as a part of the evaluation of severe asthma. The authors reported only one case had moderate bleeding during the procedure that was well controlled locally.

During the last 100 years, bronchoscopy has been used to study asthma with all types of severity. The majority of studies reported the safety of the procedure among this population with mild and

well-tolerated side effects. Further, bronchoscopy adds information that could be a cornerstone in directing future therapy of asthma and, in our opinion, it should be performed in the work-up of severe asthma patients due to its usefulness and safety.

Funding

Instituto de Salud Carlos III, Ministry of Health of Spain (PI19/01521) and endorsed by the asthma research board of SEPAR.

Conflict of interest

Authors declare no conflict of interest in relation to this editorial.

Borja G. Cosio declares speaker fees, advisory board fees or research grants from ASTRAZENCA, TEVA, SANOFI, CHIESI, GSK and NOVARTIS outside the submitted work.

References

- Plaza Moral V, Alobid I, Alvarez Rodriguez C, Blanco Aparicio M, Ferreira J, Garcia G, et al. GEMA 5.3. Spanish guideline on the management of asthma. *Open Respir Arch*. 2023;5:100277. <http://dx.doi.org/10.1016/j.opresp.2023.100277>. Epub 2023/10/27. PubMed PMID: 37886027; PubMed Central PMCID: PMCPCMC10598226.
- Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. *Chest*. 2021;160:814–30. <http://dx.doi.org/10.1016/j.chest.2021.04.013>. Epub 2021/04/23. PubMed PMID: 33887242.
- Clerf LH. Bronchoscopy as an aid in diagnosis and treatment of bronchial asthma. *J Am Med Assoc*. 1927;89:872–5. <http://dx.doi.org/10.1001/jama.1927.02690110036013>.
- Busse WW, Wanner A, Adams K, Reynolds HY, Castro M, Chowdhury B, et al. Investigative bronchoprovocation and bronchoscopy in airway diseases. *Am J Respir Crit Care Med*. 2005;172:807–16. <http://dx.doi.org/10.1164/rccm.200407-966WS>. Epub 2005/07/16. PubMed PMID: 16020805; PubMed Central PMCID: PMCPCMC2718402.
- Van Vyve T, Chanez P, Bousquet J, Lacoste JY, Michel FB, Godard P. Safety of bronchoalveolar lavage and bronchial biopsies in patients with asthma of variable severity. *Am Rev Respir Dis*. 1992;146:116–21. <http://dx.doi.org/10.1164/ajrccm/146.1.116>. Epub 1992/07/01. PubMed PMID: 1626794.
- Elston WJ, Whittaker AJ, Khan LN, Flood-Page P, Ramsay C, Jeffery PK, et al. Safety of research bronchoscopy, biopsy and bronchoalveolar lavage in asthma. *Eur Respir J*. 2004;24:375–7. <http://dx.doi.org/10.1183/09031936.04.00063003>.
- Moore WC, Evans MD, Bleecker ER, Busse WW, Calhoun WJ, Castro M, et al. Safety of investigative bronchoscopy in the Severe Asthma Research Program. *J Allergy Clin Immunol*. 2011;128. <http://dx.doi.org/10.1016/j.jaci.2011.02.042>, 328–36.e3. Epub 2011/04/19. PubMed PMID: 21496892; PubMed Central PMCID: PMCPCMC3149754.
- Humbert M, Robinson DS, Assoufi B, Kay AB, Durham SR. Safety of fibreoptic bronchoscopy in asthmatic and control subjects and effect on asthma control over two weeks. *Thorax*. 1996;51:664–9. <http://dx.doi.org/10.1136/thx.51.7.664>. Epub 1996/07/01. PubMed PMID: 8882070; PubMed Central PMCID: PMCPCMC472486.
- Good JT Jr, Kolakowski CA, Groshong SD, Murphy JR, Martin RJ. Refractory asthma: importance of bronchoscopy to identify phenotypes and direct therapy. *Chest*. 2012;141:599–606. <http://dx.doi.org/10.1378/chest.11-0741>. Epub 2011/08/13. PubMed PMID: 21835905.
- Cosio BG, Shafiek H, Mosteiro M, Iglesias A, Gomez C, Toledo-Pons N, et al. Redefining the role of bronchoscopy in the workup of severe uncontrolled asthma in the era of biologics: a prospective study. *Chest*. 2023;164:837–45. <http://dx.doi.org/10.1016/j.chest.2023.03.012>. Epub 2023/03/16. PubMed PMID: 36921895.
- Gordon IO, Husain AN, Charbeneau J, Krishnan JA, Hogarth DK. Endobronchial biopsy: a guide for asthma therapy selection in the era of bronchial thermoplasty. *J Asthma*. 2013;50:634–41. <http://dx.doi.org/10.3109/02770903.2013.794239>. Epub 2013/04/30. PubMed PMID: 23621125.
- Pretolani M, Bergqvist A, Thabut G, Dombret MC, Knapp D, Hamidi F, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathologic correlations. *J Allergy Clin Immunol*. 2017;139:1176–85. <http://dx.doi.org/10.1016/j.jaci.2016.08.009>. Epub 2016/10/26. PubMed PMID: 27609656.
- Ichikawa T, Panariti A, Audusseau S, Mogas AK, Olivenstein R, Chakir J, et al. Effect of bronchial thermoplasty on structural changes and inflammatory mediators in the airways of subjects with severe asthma. *Respir Med*. 2019;150:165–72. <http://dx.doi.org/10.1016/j.rmed.2019.03.005>. Epub 2019/04/10. PubMed PMID: 30961946.
- Muñoz-Fernandez AM, Rodrigo-Troyano A, Pajares V, Torrego A. Safety of a modified protocol of bronchial thermoplasty. *Arch Bronconeumol (Engl Ed)*. 2018;54:345–6. <http://dx.doi.org/10.1016/j.arbres.2018.01.021>. English, Spanish. Epub 2018 Feb 26. PMID: 29496284.
- Cosio BG, Shafiek H, Iglesias A, Mosteiro M, Gonzalez-Piñero A, Rodríguez M, et al. Validation of a pathological score for the assessment of bronchial biopsies in severe uncontrolled asthma: beyond blood eosinophils. *Arch Bronconeumol*. 2023;59:502–9. <http://dx.doi.org/10.1016/j.arbres.2023.05.014>. Epub 2023/07/07. PubMed PMID: 37414638.

Borja G. Cosio^{a,*}, Hanaa Shafiek^b, Alfons Torrego^c

^a Department of Respiratory Medicine, Hospital Son Espases-IdISBa-CIBERES, Palma de Mallorca, Spain

^b Chest Diseases Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt

^c Department of Respiratory Medicine, Hospital Santa Creu i Sant Pau, Barcelona, Spain

Corresponding author.

E-mail address: borja.cosio@ssib.es (B.G. Cosio).